Table 3.
HR of mortality for ESA and IV iron doses over the first 3 months of HD without restricting to patients with Hgb ≥10 g/dL in Month 4, overall and among a subset of patients with Hgb <10.0 g/dL in Month 1 of HD
| All HD patients |
||||
|---|---|---|---|---|
| Restricted to subset with Hgb <10.0 g/dL in first month of HD | ||||
| Exposure | N (%) | Adjusted HR | N (%) | Adjusted HR |
| (95% CI) | (95% CI) | |||
| Average ESA dose (units/week) over first 3 months on HD | ||||
| None | 479 (8) | 0.94 (0.59–1.51) | 103 (3) | 0.63 (0.22–1.82) |
| <5K | 711 (12) | 0.84 (0.54–1.29) | 253 (8) | 0.56 (0.25–1.27) |
| 5K–10K | 1543 (26) | 1 (Ref.) | 836 (25) | 1 (Ref.) |
| 10K–15K | 1203 (21) | 0.89 (0.64–1.24) | 773 (23) | 0.85 (0.56–1.27) |
| 15K–25K | 1223 (21) | 0.97 (0.71–1.33) | 818 (25) | 0.80 (0.53–1.20) |
| >25K | 699 (12) | 1.43 (1.02–2.01) | 537 (16) | 1.54 (1.01–2.36) |
| Average IV iron dose (mg/month) over first 3 months on HD | ||||
| None | 1008 (17) | 1.50 (1.05–2.15) | 549 (17) | 1.74 (1.08–2.79) |
| <200 | 741 (13) | 1.08 (0.72–1.62) | 407 (12) | 1.25 (0.74–2.10) |
| 200–399 | 1157 (20) | 1 (Ref.) | 605 (18) | 1 (Ref.) |
| 400–599 | 1359 (23) | 1.11 (0.78–1.57) | 783 (24) | 1.39 (0.88–2.18) |
| ≥600 | 1604 (27) | 1.24 (0.87–1.76) | 975 (29) | 1.29 (0.80–2.07) |
HR (95% CI) of all-cause mortality in left-truncated Cox model (vintage time scale) from Month 4 to Month 12 of HD; Cox models stratified by DOPPS phase, country and US dialysis chain affiliation. Adjustments: age, sex, BMI, five comorbidities (diabetes, hypertension, CHF, PVD and cancer), catheter use, serum albumin and phosphorus in Month 1 and Month 4, Hgb, TSAT and ferritin in Month 1. Note this analysis was not restricted to patients with Hgb ≥10 g/dL in Month 4.